Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting.
DNA microarray
breast cancer
gene knockdown
molecular targets
prostate cancer
sphingosine kinase
targeted therapy
transcriptome
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
12
2018
accepted:
11
03
2019
entrez:
12
4
2019
pubmed:
12
4
2019
medline:
12
4
2019
Statut:
epublish
Résumé
Sphingosine kinases 1 and 2 (SK1 and SK2) are proto-oncogenic isozymes expressed in many human tumors and associated with chemoresistance and poor prognosis. They are well-recognized therapy targets and their inhibition was shown to induce tumor volume reduction and chemosensitization in multiple cancer models. Oncogenic signaling is extremely complex and often cross-regulated. Designing molecular therapies and their combinations requires rational approaches to avoid redundant targeting or developing resistance. In this study, we have performed RNA transcriptome microarray analysis of two breast and two prostate metastatic cancer cell lines treated with siRNAs targeting SK1 or SK2. In prostate cancer cell lines SK1 knockdown (KD) has significantly changed expression of several genes including downregulation of
Identifiants
pubmed: 30971929
doi: 10.3389/fphar.2019.00303
pmc: PMC6445839
doi:
Types de publication
Journal Article
Langues
eng
Pagination
303Références
Prostate. 1999 Jun 15;40(1):50-5
pubmed: 10344723
J Biol Chem. 2000 Jun 30;275(26):19513-20
pubmed: 10751414
Int J Cancer. 2002 Mar 10;98(2):167-72
pubmed: 11857403
Nucleic Acids Res. 2003 Feb 15;31(4):e15
pubmed: 12582260
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Anticancer Drugs. 2007 Feb;18(2):105-10
pubmed: 17159597
Blood. 2008 Aug 15;112(4):1382-91
pubmed: 18511810
Curr Drug Targets. 2008 Aug;9(8):662-73
pubmed: 18691013
Immunol Cell Biol. 2011 Feb;89(2):268-74
pubmed: 20661259
Bioinformatics. 2010 Oct 1;26(19):2363-7
pubmed: 20688976
Cancer Res. 2010 Nov 1;70(21):8651-61
pubmed: 20959468
Cancer Biol Ther. 2011 Mar 1;11(5):524-34
pubmed: 21258214
Cancer Biol Ther. 2011 Apr 1;11(7):678-89
pubmed: 21307639
Adv Biol Regul. 2012 Jan;52(1):31-8
pubmed: 21791223
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Adv Cancer Res. 2013;117:143-200
pubmed: 23290780
Structure. 2013 May 7;21(5):798-809
pubmed: 23602659
Oncogene. 2014 Nov 27;33(48):5559-68
pubmed: 24276247
Tumour Biol. 2014 Dec;35(12):11895-901
pubmed: 25217320
Breast Cancer Res Treat. 2015 Jan;149(1):59-67
pubmed: 25481644
Breast Cancer Res. 2014 Oct 25;16(5):426
pubmed: 25482303
Oncotarget. 2016 Apr 26;7(17):23106-27
pubmed: 27036015
Carbohydr Polym. 2017 Jun 1;165:444-454
pubmed: 28363571
Breast Cancer Res Treat. 2017 Oct;165(3):531-543
pubmed: 28695300
Sci Rep. 2017 Jul 19;7(1):5901
pubmed: 28724986
Crit Rev Oncol Hematol. 2017 Sep;117:73-113
pubmed: 28807238
Histol Histopathol. 2018 May;33(5):433-445
pubmed: 29057430
CNS Neurosci Ther. 2018 Mar;24(3):193-201
pubmed: 29314605
J Cancer. 2018 Mar 14;9(7):1218-1230
pubmed: 29675103
Breast Cancer Res Treat. 2018 Nov;172(1):33-43
pubmed: 30043096
Acta Biochim Biophys Sin (Shanghai). 2018 Nov 1;50(11):1075-1084
pubmed: 30307473